# JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

Source: https://onco.cc/trials/nct06890065/  
OnCo record `nct06890065` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An early trial of JY231 run by Shenzhen Genocury Biotech Co., Ltd., now recruiting.

## Summary

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia is an interventional study registered as NCT06890065 by Shenzhen Genocury Biotech Co., Ltd., with 20 participants planned, started 2025-03-01, primary completion expected 2027-12. Conditions recorded: B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma. Interventions recorded: JY231 Injection. The registry gives the phase as not applicable.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06890065
- Phase: not-applicable
- Setting: An Early-Phase Exploratory Clinical Study of JY231 Injection in Relapsed/Refractory B-Cell Lymphoma/Leukemia: Safety, Tolerability, and Preliminary Efficacy
- Sponsor: Shenzhen Genocury Biotech Co., Ltd.
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06890065: https://clinicaltrials.gov/study/NCT06890065

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [JY231](https://onco.cc/drugs/jy231/)
- companies: [Genocury Biotech](https://onco.cc/companies/genocury-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct06890065.json